TriSalus Life Sciences, Inc.
TLSIHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, TriSalus Life Sciences, Inc. (TLSI) is listed under Medical Devices. With a market capitalization of $307.9M, it sits in small-cap territory. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
Market Cap
$307.9M
Beta
0.44
P/E (TTM)
—
P/E (Fwd)
-20.00
EPS (TTM)
$-1.33
EPS (Fwd)
$-0.25
ROE
—
ROA
-36.8%
Cash
$46.3M
Total Debt
$34.4M
Free CF
-$10.9M
52W Change
2.0%
Annual Financials
Cash vs Debt
Where TLSI stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, TLSI finished 13.27% above its 150-day moving average ($4.37) and 2.70% above its 200-day moving average ($4.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLSI overbought or oversold?
At the September 1, 2026 close, TLSI's RSI(14) was 24.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $46.3M in cash and $34.4M in debt, TLSI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$10.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $12.4M (2022) to $45.2M (2025), reflecting a 264% increase over the period.
TLSI's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TLSI.